• No results found

Thrombin-activatable fibrinolysis inhibitor and bacterial infections - List of publications

N/A
N/A
Protected

Academic year: 2021

Share "Thrombin-activatable fibrinolysis inhibitor and bacterial infections - List of publications"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)

UvA-DARE (Digital Academic Repository)

Thrombin-activatable fibrinolysis inhibitor and bacterial infections

Valls Serón, M.

Publication date

2011

Link to publication

Citation for published version (APA):

Valls Serón, M. (2011). Thrombin-activatable fibrinolysis inhibitor and bacterial infections.

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

(2)

List of publications 125 Cha p ter

8

List of publications

Valls Serón M, Plug T, Marquart JA, Marx PF, Herwald H, de Groot PG, Meijers JCM.

Binding characteristics of Thrombin-Activatable Fibrinolysis Inhibitor to streptococcal surface collagen-like proteins A and B. Thromb Haemost. 2011. Sep 27;106(4):609-16 Valls Serón M, Haiko J, de Groot PG, Korhonen TK, Meijers JC. Thrombin-activatable

fibrinolysis inhibitor is degraded by Salmonella enterica and Yersinia pestis. J Thromb Haemost. 2010 Oct; 8 (10): 2232-40

Marx PF, Verkleij CJ, Valls Serón M, Meijers JMC. Recent developments in

thrombin-activatable fibrinolysis inhibitor research. Mini Rev Med Chem. 2009 Sep; 9 (10): 1165-73

Padilla ND, van Vliet AK, Schoots IG, Valls Serón M, Maas MA, Peltenburg EE, de Vries A,

Niessen HW, Hack CE, van Gulik TM. C-reactive protein and natural IgM antibodies are activators of complement in a rat model of intestinal ischemia and reperfusion. Surgery.

Referenties

GERELATEERDE DOCUMENTEN

Topographic maps for LI (left) and HI (right), at Pz, for No-Go trials in the Go/No-Go task. Visual representation of one trial in the SSRT. a blue circle) on Go trials (75%

Stopping the “World’s Greatest Threat”: Canadian Policy and Rhetoric towards the Iranian Nuclear Program during Stephen Harper’s Conservative Government, 2006-2015.. by

I think joy, and like, you know, just taking care of yourself and the people around you is really important to this work because we’re in it for the long haul. we have to take care

German’s report, the Corporate Registration program plays a key role in GPEB’s regulatory framework, and is a principal mechanism through which GPEB maintains control over

Britton (1997) concluded that race and gender are contributing factors in stress and further identified the need for future researchers to explore how these intersections

These structural investigations into the mechanism for germ-line antibody recognition of carbohydrate antigens utilizing chlamydial-specific and anti-lipid A antibodies

Our structural analysis revealed that while the N- terminal region of TbFam50.360 adopted a three-helical structure similar to previously characterized trypanosome surface

I showed that data on the structural differences between the native and aggregated forms of the prion protein, obtained from multiple structural proteomics approaches